Cargando…

Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma

RATIONALE: Timely detection of pseudoprogression (PSP) is crucial for the management of patients with high-grade glioma (HGG) but remains difficult. Textural features of O-(2-[(18)F]fluoroethyl)-L-tyrosine positron emission tomography (FET-PET) mirror tumor uptake heterogeneity; some of them may be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kebir, Sied, Khurshid, Zain, Gaertner, Florian C., Essler, Markus, Hattingen, Elke, Fimmers, Rolf, Scheffler, Björn, Herrlinger, Ulrich, Bundschuh, Ralph A., Glas, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352401/ https://www.ncbi.nlm.nih.gov/pubmed/28030820 http://dx.doi.org/10.18632/oncotarget.14166

Ejemplares similares

A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma
por: Kebir, Sied, et al.
Publicado: (2020)

Value of quantitative magnetic resonance imaging T1-relaxometry in predicting contrast-enhancement in glioblastoma patients
por: Hattingen, Elke, et al.
Publicado: (2017)

Role of textural heterogeneity parameters in patient selection for 177Lu-PSMA therapy via response prediction
por: Khurshid, Zain, et al.
Publicado: (2018)

Quantitative T1‐mapping detects cloudy‐enhancing tumor compartments predicting outcome of patients with glioblastoma
por: Müller, Andreas, et al.
Publicado: (2016)

Role of fluoroethyl tyrosine positron emission tomography-computed tomography scan in differentiating ewing's sarcoma from osteomyelitis
por: Aggarwal, Hitesh, et al.
Publicado: (2019)

Regorafenib in glioblastoma recurrence: how to deal with conflicting ‘real-life’ experiences?
por: Glas, Martin, et al.
Publicado: (2019)

Quantification of O-(2-[(18)F]fluoroethyl)-L-tyrosine kinetics in glioma
por: Koopman, Thomas, et al.
Publicado: (2018)

Intravascular CNS lymphoma: Successful therapy using high-dose methotrexate-based polychemotherapy
por: Kebir, Sied, et al.
Publicado: (2012)

Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
por: Zeyen, Thomas, et al.
Publicado: (2023)

Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors
por: Schäfer, Niklas, et al.
Publicado: (2019)

Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
por: Zeyen, Thomas, et al.
Publicado: (2023)

Cost-Effectiveness of [(18)F] Fluoroethyl-L-Tyrosine for Temozolomide Therapy Assessment in Patients With Glioblastoma
por: Baguet, Tristan, et al.
Publicado: (2019)

Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization
por: Urban, Hans, et al.
Publicado: (2022)

Two Decades of Brain Tumour Imaging with O-(2-[(18)F]fluoroethyl)-L-tyrosine PET: The Forschungszentrum Jülich Experience
por: Heinzel, Alexander, et al.
Publicado: (2022)

Are we providing best-available care to newly diagnosed glioblastoma patients? Systematic review of phase III trials in newly diagnosed glioblastoma 2005–2022
por: Oster, Christoph, et al.
Publicado: (2023)

Investigation of Cerebral O-(2-[(18)F]Fluoroethyl)-L-Tyrosine Uptake in Rat Epilepsy Models
por: Stegmayr, Carina, et al.
Publicado: (2020)

Quantitative parametric maps of O-(2-[(18)F]fluoroethyl)-L-tyrosine kinetics in diffuse glioma
por: Koopman, Thomas, et al.
Publicado: (2019)

Discrepant MR and [(18)F]Fluoroethyl-L-Tyrosine PET Imaging Findings in a Patient with Bevacizumab Failure
por: Galldiks, Norbert, et al.
Publicado: (2012)

O-(2-[(18)F]fluoroethyl)-l-tyrosine PET in gliomas: influence of data processing in different centres
por: Filss, Christian P., et al.
Publicado: (2017)

Correlation of (18)F-fluoroethyl tyrosine positron-emission tomography uptake values and histomorphological findings by stereotactic serial biopsy in newly diagnosed brain tumors using a refined software tool
por: Lopez, William Omar Contreras, et al.
Publicado: (2015)

Serial O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma
por: Pöpperl, Gabriele, et al.
Publicado: (2006)

Machine Learning Facilitates Hotspot Classification in PSMA-PET/CT with Nuclear Medicine Specialist Accuracy
por: Moazemi, Sobhan, et al.
Publicado: (2020)

First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
por: Lazaridis, Lazaros, et al.
Publicado: (2022)

Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[(18)F]-fluoroethyl)-l-tyrosine PET
por: Bauer, Elena K., et al.
Publicado: (2020)

Multiple oligodendroglioma with pseudoprogression
por: Matsuyama, Junko
Publicado: (2012)

Pseudoprogression of brain tumors
por: Thust, Stefanie C., et al.
Publicado: (2018)

Pseudoprogression and Immunotherapy Phenomena
por: Waxman, Elizabeth S., et al.
Publicado: (2020)

A Fully Automated Radiosynthesis of [(18)F]Fluoroethyl-Diprenorphine on a Single Module by Use of SPE Cartridges for Preparation of High Quality 2-[(18)F]Fluoroethyl Tosylate
por: Schoultz, Bent W., et al.
Publicado: (2013)

Decision-support for treatment with (177)Lu-PSMA: machine learning predicts response with high accuracy based on PSMA-PET/CT and clinical parameters
por: Moazemi, Sobhan, et al.
Publicado: (2021)

RESOLUTE PET/MRI Attenuation Correction for O-(2-(18)F-fluoroethyl)-L-tyrosine (FET) in Brain Tumor Patients with Metal Implants
por: Ladefoged, Claes N., et al.
Publicado: (2017)

Estimating the Potential of Radiomics Features and Radiomics Signature from Pretherapeutic PSMA-PET-CT Scans and Clinical Data for Prediction of Overall Survival When Treated with (177)Lu-PSMA
por: Moazemi, Sobhan, et al.
Publicado: (2021)

Radiosynthesis and pharmacokinetics of [(18)F]fluoroethyl bufalin in hepatocellular carcinoma-bearing mice
por: Yang, Zhaoshuo, et al.
Publicado: (2017)

[(18)F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trial
por: Koh, Eng-Siew, et al.
Publicado: (2023)

Pseudoprogression in low-grade glioma
por: Slater, Jason M., et al.
Publicado: (2019)

Diagnostic accuracy of glioma pseudoprogression identification with positron emission tomography imaging: a systematic review and meta-analysis
por: Ouyang, Zhi-Qiang, et al.
Publicado: (2023)

Telemedicine in Neuro-Oncology—An Evaluation of Remote Consultations during the COVID-19 Pandemic
por: Feldheim, Jonas, et al.
Publicado: (2023)

The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, (18)F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular Factors
por: Jaber, Mohammed, et al.
Publicado: (2015)

Rapid, efficient, and economical synthesis of PET tracers in a droplet microreactor: application to O-(2-[(18)F]fluoroethyl)-L-tyrosine ([(18)F]FET)
por: Lisova, Ksenia, et al.
Publicado: (2019)

New fluoroethyl phenylalanine analogues as potential LAT1-targeting PET tracers for glioblastoma
por: Verhoeven, Jeroen, et al.
Publicado: (2019)

Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case report
por: Stoppek, Ann-Kathrin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_di63200tc8viqetr2avecfa2eh